BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00... ( NEW YORK Jan. 23 /- BVF Acquisition L...)

HOME >> BIOLOGY >> TECHNOLOGY

BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share

Date:1/23/2009

NEW YORK, Jan. 23 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value Fund, L.P. ("BVF"), announced today that it has commenced a cash tender offer to purchase any and all of the outstanding common stock of Avigen, Inc. (Nasdaq: AVGN) ("Avigen") that BVF does not own at a price of $1.00 per share under the conditions described below. The offer price represents a 35% premium over Avigen's closing stock price of $0.74 on January 8, 2009, the day prior to BVF's announcement that it was seeking to remove all incumbent Avigen directors and to elect its own slate of stockholder focused nominees (the "BVF Nominees"). BVF Partners L.P., the general partner of BVF, beneficially owns an aggregate of 8,819,600 shares of Avigen, or approximately 29.63% of the outstanding shares.

The offer is currently scheduled to expire at 12:00 midnight, New York City time, on February 23, 2009, unless the offer is extended.

On January 9, 2009, BVF delivered a notice to Avigen to call a special meeting of stockholders to remove all incumbent directors and elect the BVF Nominees, among other things. As described below, a condition to this tender offer is the BVF Nominees being elected to Avigen's Board of Directors at this special meeting of stockholders, or otherwise appointed, and constituting a majority of the directors on the Avigen board. If elected, the BVF Nominees, subject to their fiduciary duties, intend to pursue negotiations with MediciNova, Inc., related to a proposed merger with Avigen, and work to consummate the proposed merger expeditiously. Assuming the conditions to this Offer are satisfied, stockholders of Avigen would have the choice of (i) tendering their shares and receiving a fixed cash payment upon the closing of this tender offer at a premium to the market price on the day prior to b
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
2. Volcano Announces Closing of Axsun Technologies Acquisition
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
5. Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine
6. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
7. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
8. Teva and Barr Provide Update on Acquisition
9. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
10. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
11. American Oriental Bioengineering Completes Two Acquisitions

Post Your Comments:

BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00...( NEW YORK Jan. 23 /- BVF Acquisition L...)